Clinical Trial Update: A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis. [Phase 1]

View source ↗

Summary

AX-202 has completed its first-in-human Phase 1 study in healthy volunteers and individuals with psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• AX-202 (AX-202)

Snippet

Sponsor: Arxx Therapeutics | Conditions: Healthy Volunteers, Mild to Moderate Psoriasis | Phase 1 | Status: COMPLETED